PMID- 25301729
OWN - NLM
STAT- MEDLINE
DCOM- 20151001
LR  - 20240322
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 5
IP  - 23
DP  - 2014 Dec 15
TI  - MicroRNA-638 inhibits cell proliferation, invasion and regulates cell cycle by 
      targeting tetraspanin 1 in human colorectal carcinoma.
PG  - 12083-96
AB  - The expression of miR-638 was found downregulated in colorectal carcinoma (CRC) 
      in our previous study. However, the role of miR-638 in CRC remains unknown. The 
      aim of this study was to determine the function and mechanism of miR-638 in CRC. 
      Here, we verified that miR-638 was frequently downregulated in CRC tissues 
      compared with corresponding noncancerous tissues (NCTs) in an expanded CRC 
      cohort, and survival analysis showed that the downregulation of miR-638 in CRC 
      was associated with poor prognoses. The ectopic expression of miR-638 inhibited 
      CRC cell proliferation, invasion and arrest the cell cycle in G1 phase, whereas 
      the repression of miR-638 significantly promoted CRC cell growth, invasion and 
      cell cycle G1/S transition. Subsequent mechanism analyses revealed that miR-638 
      inhibited CRC cell growth, invasion and cell cycle progression by targeting 
      TSPAN1. TSPAN1 protein levels were upregulated in CRC samples and were inversely 
      correlated with miR-638 levels. More importantly, high TSPAN1 expression levels 
      in CRC tissues predicted poor overall survival, and appears to be an independent 
      prognostic factor for CRC survival. Furthermore, CpG island methylation analyses 
      revealed that the miR-638 promoter was hypermethylated in CRC and that 
      attenuating promoter methylation was sufficient to restore miR-638 expression in 
      CRC cells. Taken together, our current data demonstrate that miR-638 functions as 
      a tumor suppressor in human CRC by inhibiting TSPAN1, and that TSPAN1 is a 
      potential prognostic factor for CRC.
FAU - Zhang, Jiwei
AU  - Zhang J
AD  - Wuxi Oncology Institute, the Affiliated Hospital of Jiangnan University, Wuxi, 
      Jiangsu, 214062, China.
FAU - Fei, Bojian
AU  - Fei B
AD  - Department of Surgical Oncology, the Affiliated Hospital of Jiangnan University, 
      Wuxi, Jiangsu, 214062, China.
FAU - Wang, Qifeng
AU  - Wang Q
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 
      200032, China.
FAU - Song, Mingxu
AU  - Song M
AD  - Wuxi Oncology Institute, the Affiliated Hospital of Jiangnan University, Wuxi, 
      Jiangsu, 214062, China.
FAU - Yin, Yuan
AU  - Yin Y
AD  - Wuxi Oncology Institute, the Affiliated Hospital of Jiangnan University, Wuxi, 
      Jiangsu, 214062, China.
FAU - Zhang, Binbin
AU  - Zhang B
AD  - Wuxi Oncology Institute, the Affiliated Hospital of Jiangnan University, Wuxi, 
      Jiangsu, 214062, China.
FAU - Ni, Shujuan
AU  - Ni S
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 
      200032, China.
FAU - Guo, Weijie
AU  - Guo W
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      200032, China.
FAU - Bian, Zehua
AU  - Bian Z
AD  - Wuxi Oncology Institute, the Affiliated Hospital of Jiangnan University, Wuxi, 
      Jiangsu, 214062, China.
FAU - Quan, Chao
AU  - Quan C
AD  - Wuxi Oncology Institute, the Affiliated Hospital of Jiangnan University, Wuxi, 
      Jiangsu, 214062, China.
FAU - Liu, Zhihui
AU  - Liu Z
AD  - Wuxi Oncology Institute, the Affiliated Hospital of Jiangnan University, Wuxi, 
      Jiangsu, 214062, China.
FAU - Wang, Yugang
AU  - Wang Y
AD  - Department of Urology, University of Michigan Comprehensive Cancer Center, Ann 
      Arbor, MI 48109-5942, USA.
FAU - Yu, Jian
AU  - Yu J
AD  - State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, 
      Shanghai Jiao Tong University School of Medicine, Shanghai, 200032, China.
FAU - Du, Xiang
AU  - Du X
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 
      200032, China.
FAU - Hua, Dong
AU  - Hua D
AD  - Wuxi Oncology Institute, the Affiliated Hospital of Jiangnan University, Wuxi, 
      Jiangsu, 214062, China.
FAU - Huang, Zhaohui
AU  - Huang Z
AD  - Wuxi Oncology Institute, the Affiliated Hospital of Jiangnan University, Wuxi, 
      Jiangsu, 214062, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (MIRN638 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (TSPAN1 protein, human)
RN  - 0 (Tetraspanins)
SB  - IM
MH  - Animals
MH  - Base Sequence
MH  - Blotting, Western
MH  - Cell Cycle/*genetics
MH  - *Cell Proliferation
MH  - Colorectal Neoplasms/*genetics/metabolism/pathology
MH  - DNA Methylation/genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/genetics
MH  - Genes, Tumor Suppressor
MH  - Heterografts
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - MicroRNAs/*genetics
MH  - Middle Aged
MH  - Molecular Sequence Data
MH  - Neoplasm Invasiveness/genetics
MH  - Oligonucleotide Array Sequence Analysis
MH  - Proportional Hazards Models
MH  - Real-Time Polymerase Chain Reaction
MH  - Tetraspanins/*biosynthesis
MH  - Transcriptome
PMC - PMC4322991
EDAT- 2014/10/11 06:00
MHDA- 2015/10/02 06:00
PMCR- 2014/12/01
CRDT- 2014/10/11 06:00
PHST- 2014/07/19 00:00 [received]
PHST- 2014/09/16 00:00 [accepted]
PHST- 2014/10/11 06:00 [entrez]
PHST- 2014/10/11 06:00 [pubmed]
PHST- 2015/10/02 06:00 [medline]
PHST- 2014/12/01 00:00 [pmc-release]
AID - 2499 [pii]
AID - 10.18632/oncotarget.2499 [doi]
PST - ppublish
SO  - Oncotarget. 2014 Dec 15;5(23):12083-96. doi: 10.18632/oncotarget.2499.